MetLife Investment Management LLC Purchases 6,792 Shares of Immunome, Inc. $IMNM

MetLife Investment Management LLC boosted its stake in Immunome, Inc. (NASDAQ:IMNM) by 19.1% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 42,411 shares of the company’s stock after purchasing an additional 6,792 shares during the quarter. MetLife Investment Management LLC’s holdings in Immunome were worth $285,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in IMNM. BNP Paribas Financial Markets bought a new stake in shares of Immunome in the fourth quarter worth about $70,000. ANTIPODES PARTNERS Ltd bought a new stake in shares of Immunome in the first quarter worth about $95,000. KLP Kapitalforvaltning AS increased its holdings in shares of Immunome by 140.8% in the first quarter. KLP Kapitalforvaltning AS now owns 17,100 shares of the company’s stock worth $115,000 after acquiring an additional 10,000 shares in the last quarter. Teacher Retirement System of Texas increased its holdings in shares of Immunome by 49.0% in the first quarter. Teacher Retirement System of Texas now owns 17,360 shares of the company’s stock worth $117,000 after acquiring an additional 5,712 shares in the last quarter. Finally, Arizona State Retirement System increased its holdings in shares of Immunome by 66.2% in the first quarter. Arizona State Retirement System now owns 18,764 shares of the company’s stock worth $126,000 after acquiring an additional 7,476 shares in the last quarter. Institutional investors own 44.58% of the company’s stock.

Immunome Stock Performance

Shares of NASDAQ IMNM opened at $9.40 on Tuesday. The stock has a 50 day moving average price of $9.89 and a 200 day moving average price of $8.83. Immunome, Inc. has a 52 week low of $5.15 and a 52 week high of $16.73. The stock has a market capitalization of $818.18 million, a PE ratio of -3.05 and a beta of 1.92.

Immunome (NASDAQ:IMNM) last issued its quarterly earnings results on Wednesday, August 6th. The company reported ($0.50) EPS for the quarter, beating the consensus estimate of ($0.52) by $0.02. The firm had revenue of $4.02 million during the quarter, compared to analysts’ expectations of $1.03 million. Immunome had a negative return on equity of 76.10% and a negative net margin of 1,687.08%. As a group, research analysts forecast that Immunome, Inc. will post -2.21 EPS for the current year.

Analyst Ratings Changes

IMNM has been the subject of several recent analyst reports. Evercore ISI initiated coverage on Immunome in a report on Friday, August 22nd. They issued an “outperform” rating and a $18.00 price target for the company. Craig Hallum started coverage on Immunome in a research report on Friday. They set a “buy” rating and a $26.00 price objective for the company. Wall Street Zen raised Immunome from a “sell” rating to a “hold” rating in a research report on Thursday, May 22nd. Guggenheim reaffirmed a “buy” rating and set a $25.00 price objective on shares of Immunome in a research report on Monday, August 25th. Finally, JPMorgan Chase & Co. reduced their price objective on Immunome from $23.00 to $22.00 and set an “overweight” rating for the company in a research report on Thursday, August 7th. Nine research analysts have rated the stock with a Buy rating, According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $22.89.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.